FOLD Quote, Financials, Valuation and Earnings

Immuneering has a net margin of -4.76% compared to Amicus Therapeutics's net margin of --. Amicus Therapeutics's return on equity of -71.17% beat Immuneering's return on equity of --.

Amicus Therapeutics has a consensus price target of --, signalling upside risk potential of 77.41%. On the other hand Immuneering has an analysts' consensus of -- which suggests that it could grow by 469.57%. Given that Immuneering has higher upside potential than Amicus Therapeutics, analysts believe Immuneering is more attractive than Amicus Therapeutics.

Amicus Therapeutics has a beta of 0.599, which suggesting that the stock is 40.114% less volatile than S&P 500. In comparison Immuneering has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immuneering offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Immuneering pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $141.5M, which are larger than Immuneering quarterly revenues of --. Amicus Therapeutics's net income of -$6.7M is higher than Immuneering's net income of -$14.6M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Immuneering's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 6.00x versus 203.15x for Immuneering. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of -4.76% compared to Amicus Therapeutics's net margin of -236.04%. Amicus Therapeutics's return on equity of -71.17% beat Insmed's return on equity of --.

Amicus Therapeutics has a consensus price target of --, signalling upside risk potential of 77.41%. On the other hand Insmed has an analysts' consensus of $88.25 which suggests that it could grow by 26.5%. Given that Amicus Therapeutics has higher upside potential than Insmed, analysts believe Amicus Therapeutics is more attractive than Insmed.

Amicus Therapeutics has a beta of 0.599, which suggesting that the stock is 40.114% less volatile than S&P 500. In comparison Insmed has a beta of 1.103, suggesting its more volatile than the S&P 500 by 10.328%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $141.5M, which are larger than Insmed quarterly revenues of $93.4M. Amicus Therapeutics's net income of -$6.7M is higher than Insmed's net income of -$220.5M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 6.00x versus 32.03x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals has a net margin of -4.76% compared to Amicus Therapeutics's net margin of -104.98%. Amicus Therapeutics's return on equity of -71.17% beat Ionis Pharmaceuticals's return on equity of -93.21%.

Amicus Therapeutics has a consensus price target of --, signalling upside risk potential of 77.41%. On the other hand Ionis Pharmaceuticals has an analysts' consensus of $61.36 which suggests that it could grow by 68.89%. Given that Amicus Therapeutics has higher upside potential than Ionis Pharmaceuticals, analysts believe Amicus Therapeutics is more attractive than Ionis Pharmaceuticals.

Amicus Therapeutics has a beta of 0.599, which suggesting that the stock is 40.114% less volatile than S&P 500. In comparison Ionis Pharmaceuticals has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.148%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Ionis Pharmaceuticals pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $141.5M, which are larger than Ionis Pharmaceuticals quarterly revenues of $133.8M. Amicus Therapeutics's net income of -$6.7M is higher than Ionis Pharmaceuticals's net income of -$140.5M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Ionis Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 6.00x versus 6.60x for Ionis Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Tonix Pharmaceuticals Holding has a net margin of -4.76% compared to Amicus Therapeutics's net margin of -503.65%. Amicus Therapeutics's return on equity of -71.17% beat Tonix Pharmaceuticals Holding's return on equity of -150.01%.

Amicus Therapeutics has a consensus price target of --, signalling upside risk potential of 77.41%. On the other hand Tonix Pharmaceuticals Holding has an analysts' consensus of $5.83 which suggests that it could grow by 1476.58%. Given that Tonix Pharmaceuticals Holding has higher upside potential than Amicus Therapeutics, analysts believe Tonix Pharmaceuticals Holding is more attractive than Amicus Therapeutics.

Amicus Therapeutics has a beta of 0.599, which suggesting that the stock is 40.114% less volatile than S&P 500. In comparison Tonix Pharmaceuticals Holding has a beta of 2.232, suggesting its more volatile than the S&P 500 by 123.214%.

Amicus Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tonix Pharmaceuticals Holding offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amicus Therapeutics pays -- of its earnings as a dividend. Tonix Pharmaceuticals Holding pays out -- of its earnings as a dividend.

Amicus Therapeutics quarterly revenues are $141.5M, which are larger than Tonix Pharmaceuticals Holding quarterly revenues of $2.8M. Amicus Therapeutics's net income of -$6.7M is higher than Tonix Pharmaceuticals Holding's net income of -$14.2M. Notably, Amicus Therapeutics's price-to-earnings ratio is -- while Tonix Pharmaceuticals Holding's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amicus Therapeutics is 6.00x versus 0.58x for Tonix Pharmaceuticals Holding. Usually stocks with elevated PS ratios are considered overvalued.